Cargando…

Using a Vancomycin PBPK Model in Special Populations to Elucidate Case‐Based Clinical PK Observations

Simultaneous changes in several physiological factors may contribute to the large pharmacokinetic (PK) variability of vancomycin. This study was designed to systematically characterize the effects of multiple physiological factors to the altered PK of vancomycin observed in special populations. A va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emoto, Chie, Johnson, Trevor N., McPhail, Brooks T., Vinks, Alexander A., Fukuda, Tsuyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915605/ https://www.ncbi.nlm.nih.gov/pubmed/29446256 http://dx.doi.org/10.1002/psp4.12279

Ejemplares similares

PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants
por: Emoto, Chie, et al.
Publicado: (2018)

Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter
por: Emoto, C, et al.
Publicado: (2016)

A Theoretical Physiologically‐Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition
por: Emoto, Chie, et al.
Publicado: (2019)

Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients
por: van Hoogdalem, Matthijs W., et al.
Publicado: (2020)

Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants
por: Emoto, C, et al.
Publicado: (2015)

1574. Predictive Ability and Bias of Vancomycin Population PK Models in an Obese Adult Population
por: Sabourenkov, Paul E, et al.
Publicado: (2019)

PBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practice
por: Ferreira, Abigail, et al.
Publicado: (2021)

Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content
por: Emoto, C, et al.
Publicado: (2013)

A compatibility evaluation between the physiologically based pharmacokinetic (PBPK) model and the compartmental PK model using the lumping method with real cases
por: Ryu, Hyo-jeong, et al.
Publicado: (2022)

Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women
por: Dallmann, André, et al.
Publicado: (2018)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVVH: A Prospective Population PK/PD Analysis
por: Wang, Chuhui, et al.
Publicado: (2021)

Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants
por: Emoto, C, et al.
Publicado: (2016)

Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys
por: Cheng, Yaofeng, et al.
Publicado: (2021)

PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing
por: Chen, Yewei, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population
por: Freriksen, Jolien J. M., et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory
por: Calvier, Elisa A. M., et al.
Publicado: (2018)

The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells
por: Saleh, Mohammed A.A., et al.
Publicado: (2023)

Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator
por: Ezuruike, Udoamaka, et al.
Publicado: (2022)

Lipids in Liver Failure Syndromes: A Focus on Eicosanoids, Specialized Pro-Resolving Lipid Mediators and Lysophospholipids
por: Artru, Florent, et al.
Publicado: (2022)

PBPK modeling and simulation in drug research and development
por: Zhuang, Xiaomei, et al.
Publicado: (2016)

Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations
por: Monteiro, Joaquim F., et al.
Publicado: (2018)

Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects
por: Cui, Cheng, et al.
Publicado: (2021)

Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers
por: Wedagedera, Janak R., et al.
Publicado: (2022)

Advanced In Vivo Prediction by Introducing Biphasic Dissolution Data into PBPK Models
por: Denninger, Alexander, et al.
Publicado: (2023)

Observation of the decay $\Xi^-_b \to pK^- K^-$
por: Mathad, Abhijit
Publicado: (2017)

A Workflow for Global Sensitivity Analysis of PBPK Models
por: McNally, Kevin, et al.
Publicado: (2011)

PBPK Modeling on Organs-on-Chips: An Overview of Recent Advancements
por: Yang, Yi, et al.
Publicado: (2022)

Permeability of Gemcitabine and PBPK Modeling to Assess Oral Administration
por: Ferreira, Abigail, et al.
Publicado: (2021)

Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach
por: Liu, Qingxia, et al.
Publicado: (2022)

Characterization of prickle isoform-specific pk (pk1) and pk (sple1) mutations in Drosophila melanogaster
por: Lilienthal, Anthony J, et al.
Publicado: (2022)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
por: Lee, Tien‐Yi, et al.
Publicado: (2022)

PBPK Model for Atrazine and Its Chlorotriazine Metabolites in Rat and Human
por: Campbell, Jerry L., et al.
Publicado: (2016)

Where Do PBPK Models Stand in Pharmacometrics and Systems Pharmacology?
por: Jamei, Masoud
Publicado: (2020)

Current PBPK Models: Are They Predicting Tissue Drug Concentration Correctly?
por: Ibarra, Manuel, et al.
Publicado: (2020)

PBPK model reporting template for chemical risk assessment applications
por: Tan, Yu-Mei, et al.
Publicado: (2020)

PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease
por: Montanha, Maiara Camotti, et al.
Publicado: (2022)

PKQuest: PBPK modeling of highly lipid soluble and extracellular solutes
por: Levitt, David G.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1obr4jcmqdjr0toj2lqcbeoclh